[鼻内抗组胺药治疗变应性鼻炎的疗效：一项荟萃分析]
[Efficacy of intranasal antihistamine in the treatment of allergic rhinitis: a meta-analysis].
作者信息
Feng Shaoyan, Deng Chuntao, Li Lei, Liao Wei, Fan Yunping, Xu Geng, Li Huabin
机构信息
Department of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.
Email:
出版信息
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Oct;49(10):832-8.
OBJECTIVE
To systematically evaluate the efficacy of intranasal antihistamine in the treatment of allergic rhinitis.
METHODS
The randomized controlled trials (RCT) about intranasal antihistamines for the treatment of allergic rhinitis between January 1985 and January 2014 were searched in OVID, PubMed, EMBASE, CNKI, WanFang Data and Cochrane Library. Two reviewers independently screened the literatures, extracted the data, and evaluated the methodological quality, then meta-analysis was performed by using RevMan 5.1 software.
RESULTS
A total of thirteen RCTs were included. The results of meta-analysis showed that the efficacy of intranasal antihistamine group was superior to the placebo group in total nasal symptom scores (TNSS), the difference was significant[WMD = -1.96, 95%CI (-2.06;-1.85), P < 0.01], and individual nasal symptom scores (blocked nose, rhinorrhea, and sneezing) [WMD = -0.18, 95%CI (-0.28;-0.08); WMD = -0.45, 95%CI (-0.52;-0.38); WMD = -0.41, 95%CI (-0.58;-0.24), all P < 0.01], with significant differences. There was no significant difference between the intranasal antihistamine group and the corticosteroid group in TNSS [WMD = -1.51, 95%CI (-3.51;0.49), P = 0.14], but the intranasal antihistamines group was superior to the corticosteroid group in individual nasal symptom scores (blocked nose, rhinorrhea, and sneezing) [WMD = -0.23, 95%CI (-0.40;-0.06); WMD = -0.35, 95%CI (-0.65;-0.05); WMD = -0.25, 95%CI (-0.42;-0.08), all P < 0.05], with significant differences. The intranasal antihistamine group was superior to the oral antihistamines group in TNSS [WMD = -0.88, 95%CI (-1.51;-0.25), P < 0.01].
CONCLUSION
Intranasal antihistamine is effective in the control of nasal symptoms in AR patients.
目的
系统评价鼻用抗组胺药治疗变应性鼻炎的疗效。
方法
检索1985年1月至2014年1月期间在OVID、PubMed、EMBASE、中国知网、万方数据和考克兰图书馆中关于鼻用抗组胺药治疗变应性鼻炎的随机对照试验（RCT）。两名研究者独立筛选文献、提取数据并评估方法学质量，然后使用RevMan 5.1软件进行荟萃分析。
结果
共纳入13项RCT。荟萃分析结果显示，鼻用抗组胺药组在总鼻症状评分（TNSS）方面的疗效优于安慰剂组，差异有统计学意义[加权均数差（WMD）=-1.96，95%可信区间（CI）（-2.06；-1.85），P<0.01]，在各个鼻症状评分（鼻塞、流涕和打喷嚏）方面也有显著差异[WMD=-0.18，95%CI（-0.28；-0.08）；WMD=-0.45，95%CI（-0.52；-0.38）；WMD=-0.41，95%CI（-0.58；-0.24），均P<0.01]。鼻用抗组胺药组与皮质类固醇组在TNSS方面无显著差异[WMD=-1.51，95%CI（-3.51；0.49），P=0.14]，但在各个鼻症状评分（鼻塞、流涕和打喷嚏）方面，鼻用抗组胺药组优于皮质类固醇组[WMD=-0.23，95%CI（-0.40；-0.06）；WMD=-0.35，95%CI（-0.65；-0.05）；WMD=-0.25，95%CI（-0.42；-0.08），均P<0.05]，差异有统计学意义。鼻用抗组胺药组在TNSS方面优于口服抗组胺药组[WMD=-0.88，95%CI（-1.51；-0.25），P<0.01]。
结论
鼻用抗组胺药对控制变应性鼻炎患者的鼻症状有效。
Zotero 插件